Highly efficient genome editing in hematopoietic stem and progenitor cells
Ribonucleoproteins (RNPs) are frequently applied for therapeutic gene editing as well as fundamental research, because the method is fast, viral free, and does not rely on clonal selection. We evaluated various parameters to genetically engineer human hematopoietic stem progenitor cells (HSPCs) using spCas9-RNPs and achieve gene editing efficiencies up to 80%. We find that single guide RNA (sgRNA) design is critical to achieve high gene editing efficiencies. However, finding effective sgRNAs for HSPCs can be challenging, while the contribution of numerous in silico models is unclear. Here we established a time- and cost-efficient in vitro transcribed sgRNA screening model in K562 cells to identify sgRNAs that are effective in HSPCs using RNP delivery. We show that this simple screening method outperforms all in silico prediction models. Our data demonstrates that most in silico sgRNA prediction models are ineffective and we make recommendations to potentially improve their accuracy. We report that gene editing is equally efficient in distinct CD34+ HSPC subpopulations. Furthermore, no effects on cell proliferation, differentiation or in vitro hematopoietic lineage commitment were observed. Finally, no upregulation of p21 expression was found, suggesting unperturbed HSPC homeostasis. Key pointsO_LIIn vitro transcribed single sgRNAs (IVTsgRNA) screening in K562 outperforms in silico modeling C_LIO_LIHematopoietic stem and progenitor cells are equally targeted by Ribonucleoproteins (RNPs) C_LIO_LIHematopoietic stem and progenitor cells show no induction of p21 expression or effects on differentiation, proliferation and lineage commitment C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=158 SRC="FIGDIR/small/423329v2_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@279812org.highwire.dtl.DTLVardef@170fe3dorg.highwire.dtl.DTLVardef@1438cdforg.highwire.dtl.DTLVardef@1d5c2ab_HPS_FORMAT_FIGEXP M_FIG C_FIG